



## FINANCIAL CONTRIBUTION AGREEMENT

This Financial Contribution Agreement (“Agreement”) is made between:

SANOFI A/S, a company duly organized under the laws of Denmark under the business identity number 19064301 and having its registered office located at Vibenshuset, Lyngbyvej 2, 2100 København Ø - Denmark (hereinafter referred to as “Sanofi”)

and

Eksemforening with chairperson Anne Vastrup, Hvidovrevej 108, 1. tv., 2650 Hvidovre, Denmark (“Recipient”)

### WHEREAS

- A. Sanofi is a diversified human healthcare Sanofi engaged in the research, design, development, production, marketing, distribution and sale of medicinal products and services;
- B. Recipient is Eksemforening with chairperson Anne Vastrup
- C. Recipient appointed Molecule Consultancy, a company with registered address: Dampfærgevej 27 2100 København (“Organizer”), to take care of the execution of the disease awareness initiative ‘forbedret patientrejse’, for the website of Eksemforening. Sanofi will pay Molecule Consultancy directly.
- D. Recipient will use the funds to increasing awareness of chronic skin diseases and in particular eczema with the project” ABDEKsem – fra information til handling”.
- E. Recipient has requested Sanofi to support Recipient in the project by means of a financial contribution and Sanofi has agreed to do so. The transferal of value from Sanofi to the individual associations is 25 000 DKK.

**NOW THEREFORE**, the parties hereto agree as follows:

### 1. Obligations of Sanofi

- 1.1 Subject to the terms and conditions of this Agreement, Sanofi shall support the Project by means of a financial contribution in the amount of 25 000 DKK. This contribution will be paid to Molecule Consultancy. The disease awareness initiative is co-sponsored by other pharma companies. The initiative is owned by the Recipient and produced in cooperation with the agency Molecule.
- 1.2 The Financial Contribution will be paid within 30 (thirty) calendar days following the receipt of an invoice, which is to be sent after the effective date of this Agreement.
- 1.3 Invoices must contain the following information:



- Sanofi name and address
- Sanofi's VAT registration number:
- Sanofi's Purchase Order number *PO number to be provided later*
- Invoice date
- Unique invoice number
- Recipient's bank account details
 

Bank Account Number
Name and Address of Bank
IBAN code
BIC / SWIFT code
- Any VAT references as required (Recipient is responsible for the correct VAT treatment)

1.4 Invoices should be sent by e-mail to [invoicesDK@sanofi.com](mailto:invoicesDK@sanofi.com) (one PDF or TIFF file per message) containing one request for payment and any attachments."

## 2 Obligations of Recipient

2.1 The Financial Contribution is given solely for the organization of the Project and shall not be used by Recipient for any other purpose without Sanofi's prior written consent.

A more detailed description of the Project, including a budget, is attached hereto as Exhibit A.

2.2 Recipient acknowledges the fact that Sanofi is a pharmaceutical company and can only financially support the Project if the Project as such meets the requirements of the EFPIA Member Association's Code of Practice in the country. In view thereof, Recipient represents and warrants that in the organization of the Project it shall abide by aforesaid requirements and, more generally, refrain from any acts and activities that (may) affect the legitimacy of Sanofi's Financial Contribution.

2.3 At Sanofi's request, Recipient shall fully disclose to Sanofi how the Financial Contribution has actually been spent.

2.4 Recipient shall clearly and legibly state in its communications related to the Project that the Project was 'made possible in part by Sanofi.

2.4 In return for the Financial Contribution provided by Sanofi, Recipient shall execute the disease awareness initiative as described in the application.

## 3. Transparency

3.1 Parties agree that the Financial Contribution made by Sanofi under this Agreement is subject to the provisions on disclosure of transfers of value between pharmaceutical companies, patient organizations and healthcare organizations as set forth in the EFPIA Member Association's Code of Practice in Recipient's country of registration (the "National Code of Practice").

3.2 Parties agree that Sanofi's local affiliate in Recipient's country of registration, Sanofi A/S Denmark, will take care of disclosure of the Financial Contribution in accordance with the relevant provisions of the National Code of Practice. To that end, Recipient hereby authorizes Sanofi to share with its local affiliate all information and details pertaining to Recipient and



this Agreement as Sanofi's local affiliate may require for disclosure purposes in line with the National Code of Practice.

#### **4. Data Protection**

The Parties will process all personal data obtained during the term of this Agreement in accordance with applicable data protection laws and regulations including but not limited to the General Data Protection Regulation (EU) 2016/679 and its amendments.

#### **5. Compliance Undertakings**

##### **5.1 Parties represent and warrant that**

- in the execution of this Agreement they will comply with all applicable laws and (self-) regulations, including - but not limited to - the National Code of Practice (as defined in Article 3.2 above), data protection and anti-bribery legislation such as the UK Bribery Act 2010; and
- they, and where relevant, their directors, officers, employees, agents or subcontractors shall not, directly or indirectly pay or promise to pay, or authorize the payment of any money, or give, promise to give or authorize the giving of anything of value to any government official, healthcare professional or person affiliated with a healthcare organization to obtain or retain business or secure improper advantage to Sanofi.

5.2 Parties acknowledge that the Financial Contribution of Sanofi does not take effect and is not intended to take effect as an incentive or reward for Recipient's past, present or future willingness to prescribe, administer, recommend (including formulary recommendations), purchase, pay for, reimburse, authorize, approve or supply any product or service sold or provided by Sanofi or as an incentive to grant an interview for any sales or marketing purposes.

#### **6 Miscellaneous**

6.1 During the term of this Agreement and thereafter, each party shall keep in trust and confidence and not disclose to others all information it receives from the other party, provided however that these non-disclosure obligations do not apply to such (portion of) information that (i) at the time of disclosure is available in the public domain, (ii) after disclosure becomes available in the public domain through no fault of the receiving party, (iii) is required to be disclosed under applicable laws or (self-) regulations, including the National Code of Practice (as defined in Article 3.2 above), or (iv) is already in the possession of the other party.

6.2 This Agreement shall not be assigned or otherwise transferred by either party without the prior written consent of the other party; provided however that Sanofi may assign this Agreement to any of its affiliates or to a successor to its business (whether by merger, a sale of all or substantially all of its assets relating to this Agreement, a sale of its capital stock, or otherwise).

6.3 Either party may terminate this Agreement with immediate effect by written notice to the other party, if the other party commits a breach of this Agreement and the breach is not remedied within thirty (30) days after service of written notice requiring the same. If a party terminates this Agreement in accordance with this Article 6.3, the other party shall not be



entitled to any compensation, indemnity or damages or other payment in respect of such termination. Article 3, Article 5.0, Articles 7.2 and 7.3 and all other provisions of this Agreement, including any Exhibit, that expressly or by their nature survive termination of this Agreement, shall continue in full force and effect subsequent to and notwithstanding such termination.

6.4 Sanofi shall have the right during the term of this Agreement and three (3) years thereafter to audit whether Recipient's use of the Financial Contribution is in accordance with this Agreement.

## 7. Effective Date, Governing Law and Dispute Resolution

7.1 This Agreement becomes effective when signed by an authorized representative of each party. A signed Agreement may be delivered by any reasonable means, including facsimile or other electronic transmission

7.2 The Agreement shall be governed by the laws of Denmark without reference to its conflict of laws provisions. The Parties shall try to solve by prior good faith negotiations any difficulties that may arise between them in the performance or construction of the Agreement. Should the Parties fail to reach an agreement, the Parties agree to submit the dispute to the exclusive jurisdiction of the competent court of Copenhagen, notwithstanding plurality of defendants, summary proceedings or impleader.

IN WITNESS WHEREOF, the Parties have duly executed this Agreement.

### SANOFI

Signature:

  
[Birgitte Fyhn \(Jun 9, 2025 13:19 GMT+2\)](#)

Date:

06/09/2025

Name:

Birgitte Fyhn

Title:

Head of Market Access & External  
Affairs Denmark

### Recipient

Signature\*:

  
[Anne Skov Vastrup \(Jun 9, 2025 12:54 GMT+2\)](#)

Date:

06/09/2025

Name:

Anne Vastrup

Title:

Chair Person, Eksemploren

EXHIBIT A Project description**Anmodning om støtte til ”forbedret patientrejse”, når interesserede søger oplysninger om eksem på Eksemforeningens hjemmeside*****Forbedret patientrejse: ABDEksem – fra information til handling***

Eksemforeningen har gennem årene lavet forskellig information målrettet forskellige målgrupper – patienter med atopisk eksem og kløknopper, såvel som information målrettet unge, voksne eller forældre til børn med eksem. Informationen består af tekster, billeder, små film og podcast udarbejdet i samarbejde med sundhedsfaglige, patienter og pårørende. Vi ser nu et behov for at få ”strømlinet” patientrejsen, så enhver patient, der besøger eksemforeningen.dk får den mest optimale patientrejse i sin søgen efter relevant information.

Vi har diskuteret muligheder for forbedret patientrejse med Molecule Consultancy, og døbt projektet ”ABDEKsem – fra information til handling”.

Vi har modtaget tilbud fra Molecule på ovenstående til i alt 347.000 kr. før moms. Eksemforeningen arbejder dog med budgetter i ”legoklods-format”, så projektet kan opstartes, selv om der ikke opnås fuld finansiering, da nogle af legoklodserne er fundament, mens andre – som f.eks. udvidelse af information om behandling – er ønskede elementer, som evt. kan komme senere.

***Økonomisk anmodning***

Vi søger støtte hos både AbbVie, Almirall, LEO Pharma, Galderma og Sanofi, og i forhåbning om at alle selskaber har lyst og mulighed for at bakke op, anmoder vi Sanofi om 25.000 kr. til projektet.

Vi håber, at I kan bevillige 25.000 kr. før moms til projektet, hvor vi gerne vil lade Molecule administrere budgettet samt stå for fakturering.

Exhibit B Budget

Projektbeskrivelse og budget:

# ABDEksem – fra information til handling

Eksemforeningen arbejder for at give patienter og pårørende viden, håb og konkrete redskaber til at opnå sygdomskontrol. I 2025 ønsker vi at optimere brugeroplevelsen og udbyttet for de mange eksem-patienter og deres pårørende, der søger information og støtte hos os for at opnå sygdomskontrol.

**Mål**

Vi vil styrke patienter og pårørendes forståelse af deres sygdom og behandlingsmuligheder, så flere får den rette hjælp og behandling i tide. Vi vil



klæde dem på til at navigere i behandlingssystemet. Og vi vil vise dem vejen, så hver patient når frem til det trin i behandlingstrappen (læge-hudlæge-hospital), som sikrer dem sygdomskontrol.

Hver patient skal vide, hvad det vil sige at være velbehandlet. Og de skal insistere på at blive det. For med den nyeste viden om eksem og med nutidens mange behandlingsmuligheder er det muligt.

Hvordan?

For at nå målet ønsker vi at optimere strukturen og indholdet på eksemforeningen.dk. En forbedret brugeroplevelse skal gøre det nemt og intuitivt at finde svar, tage næste skridt og opnå sygdomskontrol.

Projektaktiviteter:

### **1. Behovsafdækning:**

Gennem interviews med en bred gruppe af patienter (forskellige eksemtyper, aldersgrupper og sværhedsgrader) afdækkes:

- Hvor patienter søger information og på hvilke kanaler
- Hvilken information patienter efterspørger
- Hvor de møder udfordringer i behandlingssystemet
- Hvordan vi bedst kan støtte deres behov

### **2. Optimering af eksemforeningen.dk**

Ny struktur og nyt design for eksemforeningen.dk for at gøre det nemmere for brugerne at navigere og finde relevant information, inkl. kodning.

- Intuitive universer tilpasset specifikke aldersgrupper og behov, ikke mindst børnefamilier, unge og voksne

### **3. Opdatering og optimering af eksisterende materialer:**

Gennemskrivning og opdatering af eksisterende indhold med inkorporering eksisterende videoer, podcasts og informationsmaterialer. Alt valideres af sundhedsfaglig person.

- Hvad ved vi om eksem i dag
- Symptomer
- Behandling
- Livet med eksem for de forskellige målgrupper: børnefamilier, unge og voksne

### **4. Udvidelse af information om behandling:**

Involvering af relevant sundhedsfaglig person for at udarbejde ny information om nutidens mange behandlingsmuligheder, der kan give patienter håb, sygdomskontrol og en bedre hverdag. Endeligt indhold besluttet efter behovsafdækning.

- Behandlingstrappen og henvisningsprocesser fra almen praksis til specialistbehandling (hudklinik og hospital)



- Synliggørelse af, hvilke typer læger der kan hjælpe med hvilke behov
- Vise vejen til behandling med en visuel forklaring af behandlingstrappen (læge, klinik, hospital)
- Guide til ventetiden for udnyttelse af ventetiden til specialisterne
- Information om hjemmebehandling ved svær eksem

#### Effektmål:

- Flere patienter og pårørende er klædt på til mødet med sundhedssystemet og opnår derfor relevant behandling og sygdomskontrol hurtigere
- Bedre forståelse af eksem og behandlingsmuligheder på tværs af aldersgrupper
- Et mere brugervenlig, informativ og handlingsanvisende website, der guider patienter til sygdomskontrol
- Øget opmærksomhed over for både nuværende og kommende oplysnings-elementer

#### Hvorfor støtte projektet?

Med din støtte til dette projekt er du med til at give patienter og pårørende værktøjerne til at tage kontrollen over sygdommen, finde vejen gennem systemet til optimal behandling og sikre en bedre livskvalitet. Din støtte gør en konkret forskel for de mange danskere, der lever med eksem.

#### Budget

Projektaktivitet	Pris ex moms
<b>Behovsafdækning</b> Interview og bearbejdning	<b>28.000</b>
<b>Optimering af eksemforeningen.dk</b> Sitemap, struktur, målgruppesegmentering, design, ikoner og kodning	<b>174.000</b>
<b>Opdatering og optimering af eksisterende materialer</b> Research, bearbejdning og gennemskrivning af eksisterende indhold, sundhedsfaglig validering	<b>78.000</b>
<b>Udvidelse af information om behandling</b> Research, interview med sundhedsfaglig person, tekstforfatning, sundhedsfaglig validering	<b>67.000</b>
<b>Pris i alt i dkk EX moms</b>	<b>347.000</b>